<SEC-DOCUMENT>0001004878-17-000251.txt : 20171207
<SEC-HEADER>0001004878-17-000251.hdr.sgml : 20171207
<ACCEPTANCE-DATETIME>20171206180922
ACCESSION NUMBER:		0001004878-17-000251
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20171207
DATE AS OF CHANGE:		20171206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220061
		FILM NUMBER:		171243141

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosupp1235000dec-17.txt
<TEXT>
                                                Filed pursuant to Rule 424(b)(3)
                                                     Registration No. 333-220061

PROSPECTUS SUPPLEMENT
(To prospectus dated August 18, 2017)

                               CEL-SCI CORPORATION


     On July 24, 2017 the Company sold convertible notes in the principal amount
of $1,235,000 to private investors.

     On November 2, 2017 the holders of these convertible notes agreed to extend
the maturity date of their notes to September 21, 2018.

     In  consideration  for the extension of the maturity date of the notes, the
Company  issued a total of 269,652  Series RR warrants to the note  holders that
agreed to the extension.  Each Series RR warrant entitles the holder to purchase
one  share of the  Company's  common  stock at a price of $1.65 per share at any
time on or before October 30, 2022.







                  Prospectus Supplement dated December 6, 2017
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
